Coherus Biosciences | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Acadia Pharmaceuticals USD 223.92M 13.87M 2025-03
ALKERMES USD 257.31M 110.81M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amarin USD 25.13M 1.78M 2025-03
Amgen USD 5.54B 430M 2025-03
Baxter International USD 1.02B 19M 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Fujifilm JPY 344.33B 10.21B 2025-03
Gilead Sciences USD 5.99B 17M 2024-12
Ironwood Pharmaceuticals USD 3.65M 60.36M 2024-09
Merck USD 12.77B 849M 2025-03
Myriad Genetics USD 134.2M 16.7M 2025-03
Pacira USD 134.62M 12.75M 2025-03
Perrigo USD 392.3M 6.4M 2025-03
Pfizer USD 11.12B 987M 2025-03
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
Teva Pharmaceutical Industries USD 1.91B 206M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12
Xencor -45143000 40.69M 2024-09
Zoetis USD 1.6B 12M 2025-03



Coherus Biosciences Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Jul 2025.